Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
A Multicenter, Randomized, Open-Label,Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A PHASE2 clinical study on Differentiated Thyroid Cancer, this trial is completed. The trial is conducted by Suzhou Zelgen Biopharmaceuticals Co.,Ltd and has accumulated 8 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .